Session (CTI)

Health plans and value assessment bodies increasingly recognise the importance of patient experience, yet conventional real-world data (claims, EHRs, registries) rarely capture treatment burden, stigma, or cost-related non-adherence in sufficient depth. In parallel, patients and caregivers openly discuss these topics in online communities and social media. This panel will debate whether, when, and how social media listening (SML) can move beyond “insight” to become decision-relevant real-world evidence for US payer and access strategy. Panelists will explore methodological standards for SML (sampling, bias mitigation, validation), and how insights on discontinuation, switching, financial toxicity, and daily-life impact can complement traditional RWD and PRO data. A health plan or PBM perspective will consider what type of digital patient-voice evidence is credible enough to influence formulary or utilization-management discussions. An HEOR/RWE lead from industry will discuss practical use cases where SML shaped evidence generation plans, value messages, or payer engagements. A patient-community or digital-ethnography expert will highlight ethical considerations, representation of vulnerable groups, and how to avoid over-interpreting “loud voices.” The panel will use short opening statements followed by moderated debate around three questions: - What is the “minimum bar” for SML to be considered robust enough for payer dialogue? - How should SML be integrated with PROs and RWD in economic models and value dossiers? - In which therapeutic areas (e.g., oncology, rare diseases, chronic conditions) is SML most likely to change access strategy? Real-time polling and audience questions will be used to surface areas of consensus vs controversy.